|
||
Clindamycine EG-300 Pregnancy |
||
Clindamycine EG-300 crosses the placenta and can be detected in the cord blood and fetal tissue (Philipson 1973; Weinstein 1976). Clindamycine EG-300 injection contains benzyl alcohol which may also cross the placenta.
Clindamycine EG-300 pharmacokinetics are not affected by pregnancy (Philipson 1976; Weinstein 1976).
Clindamycine EG-300 is recommended for use in pregnant women for the prophylaxis of group B streptococcal disease in newborns (alternative therapy) (ACOG 782 2019); prophylaxis and treatment of Toxoplasma gondii encephalitis (alternative therapy), or Pneumocystis pneumonia (PCP) (alternative therapy) (HHS [OI adult ] 2019); bacterial vaginosis (CDC [Workowski 2015]); anthrax (Meaney-Delman 2014); or malaria (CDC 2019). Clindamycine EG-300 is also one of the antibiotics recommended for prophylactic use prior to cesarean delivery and may be used in certain situations prior to vaginal delivery in women at high risk for endocarditis (ACOG 199 2018).
Use is not recommended; an alternate drug may be preferred Excreted into human milk: Yes Comments: Infants should be monitored for side effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash), or rarely, blood in the stool.
A report of bloody stools in a 5-day-old breastfed infant may have been caused by the concurrent maternal administration of IV Clindamycine EG-300 and gentamicin. Symptoms resolved 24 hours after breastfeeding was stopped and no further difficulties reported when breastfeeding was resumed on day 6 of age, after the maternal antibiotics were stopped. Concentrations in breast milk after oral administration of Clindamycine EG-300 150 mg orally three times a day after at least 1 week of therapy have been reported at 1.2 mg/L (average, 6 hours after dosing) and at 0.3 to 1.2 mg/L between one and 6 hours after a single 150 mg dose. Peak concentrations in breast milk after oral dosing of 300 mg every six hours have been reported at 1.3 mg/L after 3.5 hours and 1.8 mg/L after 2 hours. Peak concentrations in breast milk after IV administration of Clindamycine EG-300 600 mg IV every six hours have been reported at 2.65 mg/L after 3.5 hours and 3.1 mg/L after 30 minutes.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|